| Kristofer Edward Charles Nava, MD | |
|
2235 Mayfair Dr, Owensboro, KY 42301-4519 | |
| (270) 688-1500 | |
| (270) 688-1501 |
| Full Name | Kristofer Edward Charles Nava |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 7 Years |
| Location | 2235 Mayfair Dr, Owensboro, Kentucky |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154859643 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 4301506733 (Michigan) | Secondary |
| 208600000X | Surgery | 58111 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Owensboro Health Regional Hospital | Owensboro, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Owensboro Health Medical Group Inc | 0648255034 | 358 |
News Archive
"Senate Democrats may decide to pass a U.S. health-care overhaul without Republican support if some opposition lawmakers don't agree to a plan by mid-September," Senator Charles Schumer[ D-N.Y.] said" according to Bloomberg. Schumer said Sen. Max Baucus, D-Mont., set a self-imposed deadline of Sept. 15 to lead a negotiating team, composed of three Republicans and three Democrats within his Finance Committee, to a bipartisan compromise.
The practice of removing the white cells from blood is called leukoreduction. But despite the recommendations of two national advisory committees in 10 years that voted in favor of all patients in the United States receiving leukoreduced blood, ("universal leukoreduction"), the practice is still not wholly supported in the medical community, nor recommended by the Food and Drug Administration. Part of the reason is fear of increased cost.
Dutch ovarian cancer patients who were treated at a semispecialized or specialized hospital survived longer than those treated at a general hospital, according to a study published online March 11 in the Journal of the National Cancer Institute .
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
HHS Secretary Mike Leavitt said Tuesday that it is "simply unreasonable" to think Medicare can maintain its solvency without changes to the program and that if "we start now, the change can be made over time and with genuine fairness," CQ HealthBeat reports.
› Verified 7 days ago
| Entity Name | Owensboro Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235518242 PECOS PAC ID: 0648255034 Enrollment ID: O20040621000818 |
News Archive
"Senate Democrats may decide to pass a U.S. health-care overhaul without Republican support if some opposition lawmakers don't agree to a plan by mid-September," Senator Charles Schumer[ D-N.Y.] said" according to Bloomberg. Schumer said Sen. Max Baucus, D-Mont., set a self-imposed deadline of Sept. 15 to lead a negotiating team, composed of three Republicans and three Democrats within his Finance Committee, to a bipartisan compromise.
The practice of removing the white cells from blood is called leukoreduction. But despite the recommendations of two national advisory committees in 10 years that voted in favor of all patients in the United States receiving leukoreduced blood, ("universal leukoreduction"), the practice is still not wholly supported in the medical community, nor recommended by the Food and Drug Administration. Part of the reason is fear of increased cost.
Dutch ovarian cancer patients who were treated at a semispecialized or specialized hospital survived longer than those treated at a general hospital, according to a study published online March 11 in the Journal of the National Cancer Institute .
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
HHS Secretary Mike Leavitt said Tuesday that it is "simply unreasonable" to think Medicare can maintain its solvency without changes to the program and that if "we start now, the change can be made over time and with genuine fairness," CQ HealthBeat reports.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristofer Edward Charles Nava, MD Po Box 23229, Owensboro, KY 42304-3229 Ph: (270) 688-1330 | Kristofer Edward Charles Nava, MD 2235 Mayfair Dr, Owensboro, KY 42301-4519 Ph: (270) 688-1500 |
News Archive
"Senate Democrats may decide to pass a U.S. health-care overhaul without Republican support if some opposition lawmakers don't agree to a plan by mid-September," Senator Charles Schumer[ D-N.Y.] said" according to Bloomberg. Schumer said Sen. Max Baucus, D-Mont., set a self-imposed deadline of Sept. 15 to lead a negotiating team, composed of three Republicans and three Democrats within his Finance Committee, to a bipartisan compromise.
The practice of removing the white cells from blood is called leukoreduction. But despite the recommendations of two national advisory committees in 10 years that voted in favor of all patients in the United States receiving leukoreduced blood, ("universal leukoreduction"), the practice is still not wholly supported in the medical community, nor recommended by the Food and Drug Administration. Part of the reason is fear of increased cost.
Dutch ovarian cancer patients who were treated at a semispecialized or specialized hospital survived longer than those treated at a general hospital, according to a study published online March 11 in the Journal of the National Cancer Institute .
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
HHS Secretary Mike Leavitt said Tuesday that it is "simply unreasonable" to think Medicare can maintain its solvency without changes to the program and that if "we start now, the change can be made over time and with genuine fairness," CQ HealthBeat reports.
› Verified 7 days ago
Dr. Suzanne Marie Vass Rashidian, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3821 Vincent Station Dr, Owensboro, KY 42303 Phone: 270-478-5334 Fax: 270-216-6920 | |
Dr. Christopher C Glaser, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2801 New Hartford Rd, Owensboro, KY 42303 Phone: 270-683-3720 Fax: 270-686-7331 | |
Dr. Thomas Christopher Nebel, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 2801 New Hartford Rd, Owensboro, KY 42303 Phone: 270-683-3720 Fax: 270-686-7331 | |
Dr. Jeffrey S Danetz, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1325 Triplett St, Owensboro, KY 42303 Phone: 270-688-4325 Fax: 270-687-4322 | |
Mr. Philip Anthony Decker, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2801 New Hartford Rd, Owensboro, KY 42303 Phone: 270-683-3720 Fax: 270-686-7331 | |
Dr. Roger Lea Humphrey, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 2801 New Hartford Rd, Owensboro, KY 42303 Phone: 270-683-3720 Fax: 270-686-7331 |